Evidence map›Paper›PMID 37415162›Full record

ReviewJournal of hematology & oncology2023

Tumor-associated myeloid cells in cancer immunotherapy.

Xinyu Cheng, Huilan Wang, Zhongyu Wang, Bo Zhu, Haixia Long

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Peripheral SNCADiscover oncology · 2025
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xinyu Cheng *Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Huilan Wang *Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Zhongyu WangInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Bo ZhuInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. bo.zhu@tmmu.edu.cn.
Haixia LongInstitute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China. longhaixialhx@163.com.

Funding

National College Students Innovation and Entrepreneurship Training Program 202290031033National Natural Science Foundation of China 82150119National Natural Science Foundation of China 82230095
6 · The paper itself

Abstract

Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant role on the efficacy of immune checkpoint blockade. Understanding the origin of TAMCs was found to be the essential to determining their functional heterogeneity and, developing cancer immunotherapy strategies. While myeloid-biased differentiation in the bone marrow has been traditionally considered as the primary source of TAMCs, the abnormal differentiation of splenic hematopoietic stem and progenitor cells, erythroid progenitor cells, and B precursor cells in the spleen, as well as embryo-derived TAMCs, have been depicted as important origins of TAMCs. This review article provides an overview of the literature with a focus on the recent research progress evaluating the heterogeneity of TAMCs origins. Moreover, this review summarizes the major therapeutic strategies targeting TAMCs with heterogeneous sources, shedding light on their implications for cancer antitumor immunotherapies.

Indexed as

NeoplasmsBone MarrowHematopoietic Stem CellsHumansImmunotherapyMyeloid CellsTumor MicroenvironmentCancer immunotherapyImmune checkpoint blockadeImmune evasionMyelopoiesisTumor associated myeloid cellsTumor microenvironment

Identifiers

PMID37415162
PMCPMC10324139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.